InterMune Price Target Increased to $46.00 by Analysts at Canaccord Genuity (ITMN)
Equities research analysts at Canaccord Genuity upped their price target on shares of InterMune (NASDAQ:ITMN) from $22.00 to $46.00 in a research note issued to investors on Wednesday, AnalystRatings.NET reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective points to a potential upside of 21.69% from the stock’s previous close.
Shares of InterMune (NASDAQ:ITMN) traded down 9.55% during mid-day trading on Wednesday, hitting $34.19. The stock had a trading volume of 3,308,759 shares. InterMune has a 1-year low of $8.41 and a 1-year high of $38.73. The stock has a 50-day moving average of $15.75 and a 200-day moving average of $14.57. The company’s market cap is $3.067 billion. InterMune also was the recipient of some unusual options trading activity on Tuesday. Stock traders acquired 25,056 call options on the company. This is an increase of 667% compared to the average daily volume of 3,267 call options.
A number of other analysts have also recently weighed in on ITMN. Analysts at Leerink Swann downgraded shares of InterMune from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Separately, analysts at Jefferies Group raised their price target on shares of InterMune from $7.00 to $20.00 in a research note on Wednesday. Finally, analysts at Credit Suisse raised their price target on shares of InterMune from $15.00 to $33.00 in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. InterMune presently has a consensus rating of “Buy” and an average target price of $28.64.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.